Peptide therapeutics: current status and future directions.
about
Patterning Biomaterials for the Spatiotemporal Delivery of Bioactive MoleculesFrom Mollusks to Medicine: A Venomics Approach for the Discovery and Characterization of Therapeutics from Terebridae Peptide ToxinsInhaled protein/peptide-based therapies for respiratory diseaseSynthetic Peptides as Protein MimicsAdvances in Fmoc solid-phase peptide synthesisPerspective of Use of Antiviral Peptides against Influenza VirusCNS active O-linked glycopeptidesPACAP suppresses dry eye signs by stimulating tear secretion.Efficient enzymatic cyclization of an inhibitory cystine knot-containing peptideNatural Proline-Rich Cyclopolypeptides from Marine Organisms: Chemistry, Synthetic Methodologies and Biological StatusHYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer ResponseMotif mediated protein-protein interactions as drug targetsdPABBs: A Novel in silico Approach for Predicting and Designing Anti-biofilm PeptidesClustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23Recombinant production of medium- to large-sized peptides in Escherichia coli using a cleavable self-aggregating tagOrigin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties.Direct Activation of Bax Protein for Cancer TherapyScaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitorsFully Blind Docking at the Atomic Level for Protein-Peptide Complex Structure PredictionTargeting kinase signaling pathways with constrained peptide scaffolds.Physicochemical properties and in vitro cytotoxicity of iron oxide-based nanoparticles modified with antiangiogenic and antitumor peptide A7R.A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cellsPeptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications.Innovative Therapeutics: Designer Natriuretic Peptides.Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.Role of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders.A Drug Carrier for Sustained Zero-Order Release of Peptide TherapeuticsDual functionality nanobioconjugates targeting intracellular bacteria in cancer cells with enhanced antimicrobial activity.Folding and function in α/β-peptides: targets and therapeutic applications.Extended Release of an Anti-Heparan Sulfate Peptide From a Contact Lens Suppresses Corneal Herpes Simplex Virus-1 Infection.Optimized deep-targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks.Discovering Peptide Inhibitors of Human Squalene Synthase Through Screening the Phage-Displayed Cyclic Peptide c7c Library.Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin.Effective Design of Multifunctional Peptides by Combining Compatible FunctionsIdentification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.Conformational Restriction of Peptides Using Dithiol Bis-AlkylationCentipede venoms as a source of drug leads.EGAR, A Food Protein-Derived Tetrapeptide, Reduces Seizure Activity in Pentylenetetrazole-Induced Epilepsy Models Through α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionate Receptors.Evolution of phage display technology: from discovery to application.Spermaurin, an La1-like peptide from the venom of the scorpion Scorpio maurus palmatus, improves sperm motility and fertilization in different mammalian species.
P2860
Q26744573-EC9BC18E-0C08-4BC0-BEC7-34A8218DB3ECQ26750941-3951778B-F02F-443A-8069-9435CF161357Q26751439-CF3D7C44-59A3-4AD3-8D1A-E2DDFF4E37DAQ26770255-7A6B3E9E-30D3-4AB6-841D-56D3C298A002Q26770921-D07B1BB6-013D-41B9-B6D4-857A0BC5ABE5Q26780434-D71A34DA-076F-4BE5-A79E-5D3B8EAC9FC0Q27021529-CDD83783-37FB-4BE3-A65E-204F36F83D6FQ27340456-8C135DFD-2A1F-4CAF-992D-085829049F01Q27704653-5E708979-E899-45F2-82AA-52C372A876BAQ28075671-AFA93399-58C9-4FB5-AE99-317244DF4378Q28079276-B97C68EB-D4AF-42BB-AACF-71857273B219Q28079554-6677DF1F-F770-4D8C-8493-5890C3CEEF46Q28603750-7E47BAE5-DB3C-4194-BEEF-9C1858B1279DQ28820713-C7742A98-88CC-46D2-82F0-E2DDFD2C49A0Q28831200-74F426D2-1C53-47C5-BC8E-3F4598A3BA1CQ29248355-7D17E19A-95B4-43E8-BA27-E8916F3BE696Q30353924-4E3CD755-715D-44A6-8E94-548206A35E18Q30359734-9094DB1E-995B-46A3-8AA3-0445CD59EFA6Q30393096-49D4B132-15B5-47C2-93DE-9E95F3E48FCFQ30398451-B2DA4BCA-EA68-463F-8886-14EBD91EDAC6Q30847079-A787A2DF-7A5C-428F-B3C1-81B6CB552473Q33558900-42AEFBBE-FBF4-41E5-AA80-46344C2ADF20Q33612302-60F8AFF0-538F-486E-9A56-089A1E84B58EQ33653332-D9706DB6-2A96-439C-B3D3-192A05BAC87CQ33683537-A43BEB64-29D0-498A-98E1-9E1E1CBFDA67Q33742305-A12E11FC-22E0-4A6D-900E-ADD97F9BFD05Q33912239-EF3C5F6C-0110-465E-8E61-64E1C99477CEQ33918385-91020698-6EDA-4D6F-B36F-4B748A97F39FQ34483276-39C8724F-B5B3-40C0-B715-428AAB6DA9E8Q34509564-4D6F64AF-91D3-463D-8FDE-B9969042CEF9Q35684927-2CF983E0-CE42-4EAC-806D-327A440C95E7Q35938489-CB1401EE-4636-4D89-8FB1-055C4CADB76AQ35975651-150FB9A7-AE50-406E-8D6C-CC99AE8807C7Q35994698-FDE35DFB-E0EC-440D-8172-73058C86BCF9Q36087118-0FDEB173-2DDA-4A83-A674-CAD3EF904E78Q36120663-6B704C33-2D84-4EEB-BAA3-CCCE012EEBFCQ36128041-E03043D7-3A50-49A8-A1F4-BB564682AAC9Q36174777-03BB10A5-2B30-4680-96DA-91C79318F905Q36183954-AA1A36DC-F4A8-4051-839C-01F97995AB41Q36216774-96F56380-B69F-4957-9F85-58C57FB0643F
P2860
Peptide therapeutics: current status and future directions.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Peptide therapeutics: current status and future directions.
@en
type
label
Peptide therapeutics: current status and future directions.
@en
prefLabel
Peptide therapeutics: current status and future directions.
@en
P1433
P1476
Peptide therapeutics: current status and future directions.
@en
P2093
Keld Fosgerau
Torsten Hoffmann
P304
P356
10.1016/J.DRUDIS.2014.10.003
P577
2014-10-17T00:00:00Z